Parenteral Drugs (India) (NSE:PDPL) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Mar. 2022)


NSE:PDPL Parenteral Drugs (India) Ltd NSE:PDPL
4 GF Score
Price ₹2.90
View Full Analysis

What is Parenteral Drugs (India) Cyclically Adjusted Revenue per Share?

Parenteral Drugs (India) NSE:PDPL 4 Cyclically Adjusted Revenue per Share is ₹0.00 as of Mar. 2022. GuruFocus rates NSE:PDPL with a GF Score™ of 4/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Parenteral Drugs (India)'s adjusted revenue per share for the three months ended in Mar. 2022 was ₹0.595. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Mar. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-08), Parenteral Drugs (India)'s current stock price is ₹2.90. Parenteral Drugs (India)'s Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2022 was ₹0.00. Parenteral Drugs (India)'s Cyclically Adjusted PS Ratio of today is .


Parenteral Drugs (India)  (NSE:PDPL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Parenteral Drugs (India) Cyclically Adjusted Revenue per Share Related Terms


Parenteral Drugs (India) Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Parenteral Drugs (India)'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Cyclically Adjusted Revenue per Share Chart

Parenteral Drugs (India) Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Parenteral Drugs (India) Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:PDPL vs ZTS, CTLT, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parenteral Drugs (India) Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s Cyclically Adjusted PS Ratio falls into.


NSE:PDPL
4GF Score
Parenteral Drugs (India) Ltd NSE:PDPL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parenteral Drugs (India) Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Parenteral Drugs (India)'s adjusted Revenue per Share data for the three months ended in Mar. 2022 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2022 (Change)*Current CPI (Mar. 2022)
=0.595/138.8218*138.8218
=0.595

Current CPI (Mar. 2022) = 138.8218.

Parenteral Drugs (India) Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201206 27.669 79.567 48.275
201209 27.986 82.244 47.238
201212 26.651 83.774 44.163
201303 37.287 85.687 60.409
201306 31.201 88.365 49.017
201309 28.615 91.042 43.632
201312 20.206 91.425 30.681
201403 14.351 91.425 21.791
201406 25.862 94.103 38.152
201409 22.684 96.780 32.538
201412 18.858 96.780 27.050
201503 16.854 97.163 24.080
201506 29.539 99.841 41.072
201509 26.844 101.753 36.623
201512 16.909 102.901 22.812
201603 18.155 102.518 24.584
201606 26.022 105.961 34.092
201609 21.346 105.961 27.966
201612 15.523 105.196 20.485
201703 15.933 105.196 21.026
201706 20.950 107.109 27.153
201709 25.193 109.021 32.079
201712 17.761 109.404 22.537
201803 12.386 109.786 15.662
201806 16.455 111.317 20.521
201809 2.984 115.142 3.598
201812 3.415 115.142 4.117
201903 0.791 118.202 0.929
201906 2.925 120.880 3.359
201909 2.463 123.175 2.776
201912 2.428 126.235 2.670
202003 0.244 124.705 0.272
202006 0.979 127.000 1.070
202009 1.557 130.118 1.661
202012 0.683 130.889 0.724
202103 0.862 131.771 0.908
202106 0.982 134.084 1.017
202109 0.788 135.847 0.805
202112 0.484 138.161 0.486
202203 0.595 138.822 0.595

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Parenteral Drugs (India) (NSE:PDPL) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Mar. 2022. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Parenteral Drugs (India) and its competitors.
Is Parenteral Drugs (India)'s Cyclically Adjusted Revenue per Share too high?
Parenteral Drugs (India)'s current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Parenteral Drugs (India) has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Parenteral Drugs (India)'s Cyclically Adjusted Revenue per Share compare to ZTS and CTLT?
Parenteral Drugs (India)'s Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Parenteral Drugs (India) and its competitors. Parenteral Drugs (India)'s current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parenteral Drugs (India) stock overvalued right now?
Parenteral Drugs (India) (NSE:PDPL) has a current Cyclically Adjusted Revenue per Share of ₹0.00. The current Cyclically Adjusted Revenue per Share is ₹0.00. Parenteral Drugs (India)'s overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Parenteral Drugs (India) (NSE:PDPL), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parenteral Drugs (India) Business Description

Address Navlakha Crossing, A. B. Road, Shree Ganesh Chambers, Indore, MP, IND, 452001
Parenteral Drugs (India) Ltd is a pharmaceutical company. It is principally engaged in manufacturing pharmaceutical preparations. The company manufactures products in categories like intravenous (IV) fluids, oncology, anesthesia, and export products. Its IV fluids products include carbohydrates and electrolytes, diuretics, dialysis, and irrigation solution, anti-infective and anti-fungal, and other pharmaceutical products.
4GF Score

Get the complete analysis for NSE:PDPL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price